PGP and Alzheimer disease: The mass spectrometric findings on P-gp are in contrast with the functional (R)-[11C]-verapamil PET study results, where AD patients exhibited higher binding potential of this P-gp substrate in most areas of the AD brain and lower extraction ratios compared to age-matched, healthy volunteers [58,59,60].